Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
October 2, 2024 12:44 PM 2 min read

Legal Battle Brews Over 23andMe's Customer Data Breach Settlement And Arbitration Claimants

by Vandana Singh Benzinga Editor
Follow

Last year, 23andMe Holding Co. (NASDAQ:ME) said the company learned that a threat actor accessed several individual 23andMe.com accounts through credential stuffing.

The company said the hacker accessed roughly 14,000 user accounts of the existing 14 million customers and accessed the information included in a significant number of DNA Relatives profiles (approximately 5.5 million) and Family Tree feature profiles (approximately 1.4 million).

The data breach occurred in April 2023, and the company learned about the incident in October 2023.

The company settled the lawsuits with $30 million related to the breach.

A law firm representing around 5,000 customers of genetic testing company 23andMe has raised objections to a proposed $30 million class action settlement, arguing the settlement is intentionally designed to undermine claimants' rights.

Also Read: Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not ‘Actionable Proposal' Despite Ample Time.

As per the court filing, the intervenors argue that the proposed class action settlement seeks unprecedented and extraordinary relief. They claim it aims to eliminate contractual rights between private parties, favoring 23andMe while disadvantaging the claimants.

When these individuals signed up for 23andMe's services, they were compelled to waive their right to pursue legal action in court, instead being forced into private arbitration for any disputes.

By implementing this binding contract and arbitration clause, 23andMe believed it would shield itself from lawsuits, assuming no consumer would bother with the costly arbitration process.

Reuters highlighted that 23andMe defended the injunction, arguing that it is necessary to protect the company's financial stability. The firm claims that certain mass arbitration firms are exploiting the process to secure side settlements at the expense of millions of class members.

The company contends that halting arbitration would prevent these firms from leveraging high arbitration fees for favorable deals that could negatively impact the broader class of customers.

A hearing on the proposed settlement is set for October 17.

The company is already facing a tumultuous time in public markets that witnessed a significant decline in the company's valuation, once at $6 billion.

Price Action: ME stock is up 2.95% at $0.38 at last check Wednesday.

Read Next:

  • Apple To Launch Budget iPhone in 2025, Aims for Market Share Gains from Huawei and Xiaomi

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
NewsHealth CareLegalTop StoriesGeneralBriefsStories That Matter
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...